Latent Herpesviruses of Humans
Publication: Annals of Internal Medicine
Volume 100, Number 6
Abstract
The herpesviruses that infect humans characteristically establish a latent infection that may be reactivated later. The consequences of reactivation range from asymptomatic shedding to severe disseminated infection. Varicella-zoster and herpes simplex viruses are both highly neurotropic, establishing nonreplicating infections in sensory ganglia. Latent herpes simplex virus is known to reside in neurons, and the virus-cell interactions involved have been defined to an extent. Cytomegalovirus and Epstein-Barr virus interact with peripheral blood leukocytes. Latent cytomegalovirus infection of human leukocytes has not been proved, although studies in a murine model have implicated B lymphocytes as a repository of latent virus. Epstein-Barr virus is known to persist in a non-replicating state as extrachromosomal DNA in B lymphocytes and to cause "immortalization" of the infected cell; persistence of the viral genome in epithelial cells may also result in malignant transformation, such as nasopharyngeal carcinoma.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
FENNER F, MCAUSLAN B, MIMS C, SAMBROOK J, and WHITE D eds. The Biology of Animal Viruses. 2nd ed. New York: Academic Press; 1974:452-8.
2.
STEVENS J. Latent characteristics of selected herpesviruses. Adv Cancer Res. 1978;26:227-56.
3.
HORTA-BARBOSA L, FUCILLO D, SEVER J, and ZEMAN W. Subacute sclerosing panencephalitis: isolation of measles virus from a brain biopsy. Nature. 1969;221:974-6.
4.
PADGETT B, WALKER D, ZURHEIN G, ECKROADE R, and DESSEL B. Cultivation of a papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1:1257-60.
5.
HO M. Epidemiology of cytomegalovirus infection in man. In: HO M. Cytomegalovirus: Biology and Infection. New York: Plenum Medical Book Co.; 1982:79-104.
6.
NlEDERMAN J, MlLLER G, PEARSON H, PAGANO J, and DOWALIBY J. Infectious mononucleosis: Epstein-Barr-virus shedding in saliva and the oropharynx. N Engl J Med. 1976;294:1355-9.
7.
LINDGREN K, DOUGLAS R, and COUCH R. Significance of herpesvirus hominis in respiratory secretions of man. N Engl J Med. 1968;278:517-23.
8.
RATTRAY M, COREY L, REEVES W, VONTVER L, and HOLMES K. Recurrent genital herpes among women: symptomatic v. asymptomatic virus shedding. Br J Vener Dis. 1978;54:262-5.
9.
GOLD E and NANKERVIS G. Cytomegalovirus. In: EVANS AS, ed. Viral Infections of Humans: Epidemiology and Control. 2nd ed. New York: Plenum Medical Book Co.; 1982:167-86.
10.
HOPE-SIMPSON R. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20.
11.
BATEMAN T. A Practical Synopsis of Cutaneous Diseases According to the Arrangement of Dr. Willan. 3rd ed. London: Longman, Hurst, Orme and Brown; 1814:221.
12.
VON BOKAY J. Uber den atiologischen Zusammenhang der Varizellen mit gewissen Fallen von Herpes-Zoster. Wien Klin Wochenschr. 1909;22:1323-6.
13.
KUNDRATITZ K. Experimentelle Ubertragung von Herpes-Zoster auf den Menschen und die Beziehungen von Herpes-Zoster zu Varicellen. Monatsschr Kinderheilk. 1925;29:516-23.
14.
BRUUSGAARD E. Mutual relation between zoster and varicella. Br J Dermatol Syph. 1932;44:1-24.
15.
WELLER T. Serial propagation in vitro of agents producing inclusion bodies derived from varicella and herpes zoster. Proc Soc Exp Biol Med. 1953;83:340-6.
16.
TRIEBWASSER J, HARRIS R, BRYANT R, and RHOADES E. Varicella pneumonia in adults: report of seven cases and a review of literature. Medicine (Baltimore). 1967;46:409-23.
17.
GLICK N, LEVIN S, and NELSON K. Recurrent pulmonary infarction in adult chickenpox pneumonia. JAMA. 1972;222:173-7.
18.
WILLIAMS B and CAPERS T. The demonstration of intranuclear inclusion bodies in sputum from a patient with varicella pneumonia. Am J Med. 1959;27:836-9.
19.
BASTIAN F, RABSON A, YEE C, and TRALKA T. Herpesvirus varicellae isolated from human dorsal root ganglia. Arch Pathol. 1974;97:3313.
20.
FEE C and EVARTS C. Motor paralysis of the lower extremities in herpes zoster. Cleve Clin Quart. 1968;35:169-76.
21.
RAY B and WISE G. Urinary retention associated with herpes zoster. J Urol. 1970;104:422-5.
22.
BURGOON C, BURGOON J, and BALDRIDGE G. The natural history of herpes zoster. JAMA. 1957;164:265-9.
23.
PANCOAST H and PENDERGRASS E. The occurrence of herpes zoster in Hodgkin's disease. Am J Med Sci. 1924;168:326-34.
24.
MERIGAN T and STEVENS D. Viral infections in man associated with acquired immunological deficiency states. Fed Proc. 1971;30:1858-64.
25.
STEVENS D and MERIGAN T. Interferon, antibody, and other host factors in herpes zoster. J Clin Invest. 1972;51:1170-8.
26.
GALLAGHER J and MERIGAN T. Prolonged herpes-zoster infection associated with immunosuppressive therapy. Ann Intern Med. 1979;91:842-6.
27.
JORDAN G and MERIGAN T. Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses. J Infect Dis. 1974; 130:495-501.
28.
RAND K, RASMUSSEN L, POLLARD R, ARVIN A, and MERIGAN T. Cellular immunity and herpesvirus infections in cardiac transplant patients. N Engl J Med. 1976;296:1372-7.
29.
DOLIN R, REICHMAN R, MAZUR M, and WHITLEY R. Herpes zostervaricella infections in immunosuppressed patients. Ann Intern Med. 1978;89:375-88.
30.
STEVENS D, FERRINGTON R, JORDAN G, and MERIGAN T. Cellular events in zoster vesicles: relation to clinical course and immune parameters. J Infect Dis. 1975;131:509-15.
31.
ARMSTRONG R, GURWITH M, WADDELL D, and MERIGAN T. Cutaneous interferon production in patients with Hodgkin's disease and other cancers infected with varicella or vaccinia. N Engl J Med. 1970;283:1182-7.
32.
MERIGAN T, RAND K, POLLARD R, ABDALLAH P, JORDAN G, and FRIED R. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med. 1978;298:981-7.
33.
ARVIN A, KUSHNER J, FELDMAN S, BAEHNER R, HAMMOND D, and MERIGAN T. Human leukocyte interferon for the treatment of varicella in children with cancer. N Engl J Med. 1982;306:761-5.
34.
WHITLEY R, SOONG S, DOLIN R, BETTS R, LINNEMANN C, and ALFORD C. Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med. 1982;307:971-5.
35.
SPECTOR S, HINTZ M, WYBORNY L, CONNOR J, KEENEY R, and LIAO S. Treatment of herpes virus infections in immunocompromised patients with acyclovir by continuous intravenous infusion. Am J Med. 1982;73:275-80.
36.
SEROTA F, STARR S, BRYAN C, KOCK P, PLOTKIN S, and AUGUST C. Acyclovir treatment of herpes zoster infections: use in children undergoing bone marrow transplantation. JAMA. 1982;247:2132-5.
37.
BALFOUR H, BEAN B, and LASKIN O. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med. 1983;308:1448-53.
38.
WHITLEY R, HILTY M, and HAYNES R. Vidarabine therapy of varicella in immunosuppressed patients. J Pediatr. 1982;101:125-31.
39.
PROBER C, KIRK L, and KEENEY R. Acyclovir therapy of chickenpox in immunosuppressed children—a collaborative study. J Pediatr. 1982;101:622-5.
40.
PAZIN G, ARMSTRONG J, LAM M, TARR G, JANNETTA P, and HO M. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. N Engl J Med. 1979;301:225-30.
41.
CHEESEMAN S, RUBIN R, and STEWART J. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation: effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med. 1979;300:1345-9.
42.
O'REILLY F, EVERSON L, and EMODI G. Effects of exogenous interferon in cytomegalovirus infections complicating bone marrow transplantation. Clin Immunol Immunopathol. 1976;6:51-61.
43.
TAKAHASHI M, OTSUKA T, OKUNO Y, ASANO Y, and YAZAKI T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet. 1974;2:1288-90.
44.
BRUNNELL P. Live varicella vaccine [Letter]. Lancet. 1975;1:98-9.
45.
GERSON A. Live attenuated varicella-zoster vaccine. Rev Infect Dis. 1980;2:393-407.
46.
GOODPASTURE E. Herpetic infections with special reference to involvement of the nervous system. Medicine (Baltimore). 1929;7:22343.
47.
STEVENS J and COOK M. Latent herpes simplex virus in spinal ganglia of mice. Science. 1971;173:843-5.
48.
STEVENS J, NESBURN A, and COOK M. Latent herpes simplex virus from trigeminal ganglia of rabbits with recurrent eye infection. Nature [New Biol]. 1972;235:216-7.
49.
BASTIAN F, RABSON A, YEE C, and TRALKA T. Herpesvirus hominis: isolation from human trigeminal ganglion. Science. 1972;178:306-7.
50.
BARINGER J and SWOVELAND P. Recovery of herpes-simplex virus from human trigeminal ganglions. N Engl J Med. 1973;288:648-50.
51.
BARINGER J. Recovery of herpes simplex virus from human sacral ganglions. N Engl J Med. 1974;291:828-30.
52.
FRASER N, LAWRENCE W, WROBLEWSKA Z, GILDEN D, and KOPROWSKI H. Herpes simplex type 1 DNA in human brain tissue. Proc Natl Acad Sci USA. 1981;78:6461-5.
53.
COOK M and STEVENS J. Latent herpetic infections following experimental viraemia. J Gen Virol. 1976;31:75-80.
54.
SCRIBA M. Extraneural localization of herpes simplex virus in latently infected guinea pigs. Nature. 1977;267:529-31.
55.
STEVENS J and COOK M. Maintenance of latent herpetic infection: an apparent role for anti-viral IgG. J Immunol. 1974;113:1685-93.
56.
GALLOWAY D, FENOGLIO C, and MCDOUGALL J. Limited transcription of the herpes simplex virus genome when latent in human sensory ganglia. J Virol. 1982;41:686-91.
57.
HAMMER S, RICHTER B, and HIRSCH M. Activation and suppression of herpes simplex virus in a human T lymphoid cell line. J Immunol. 1981;127:144-8.
58.
WIGDAHL B, SCHECK A, DE CLERCQ E, and RAPP F. High efficiency latency and activation of herpes simplex virus in human cells. Science. 1982;217:1145-6.
59.
SARAL R, BURNS W, LASKIN O, SANTOS G, and LIETMAN P. Acyclovir prophylaxis of herpes-simplex-virus infections: a randomized double-blind controlled trial in bone marrow transplant recipients. N Engl J Med. 1981;305:63-7.
60.
COREY L, NAHMIAS A, GUINAN M, BENEDETTI J, CRITCHLOW C, and HOLMES K. A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med. 1982;306:1313-9.
61.
BRYSON Y, DILLON M, and LOVETT M. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir: a randomized double-blind controlled trial in normal subjects. N Engl J Med. 1983;308:916-21.
62.
HILLEMAN M, LARSON V, LEHMAN E, SALERNO R, CONRAD P, and MCLEAN A. Subunit herpes simplex 2 vaccine. In: NAHMIAS A, DOWDLE W, SCHINAGI R, eds. The Human Herpesviruses: An Interdisciplinary Perspective. New York: Elsevier/North-Holland; 1981:503-6.
63.
JORDAN M. Latent infection and the elusive cytomegalovirus. Rev Infect Dis. 1983;5:205-15.
64.
NUMAZAKI Y, YANO N, MORIZUKA T, TAKAI S, and ISHIDA N. Primary infection with human cytomegalovirus: virus isolation from healthy infants and pregnant women. Am J Epidemiol. 1970;91:410-7.
65.
MONTGOMERY R, YOUNGBLOOD L, and MEDEARIS D. Recovery of cytomegalovirus from the cervix in pregnancy. Pediatrics. 1972;49:524-31.
66.
HAYES K, DANKS D, GIBAS H, and JACK I. Cytomegalovirus in human milk. N Engl J Med. 1972;287:177-8.
67.
STAGNO S, REYNOLDS D, PASS R, and ALFORD C. Breast milk and risk of cytomegalovirus infection. N Engl J Med. 1980;302:1073-6.
68.
PRINCE A, SZMUNESS W, MILLIAN S, and DAVID D. A serologic study of cytomegalovirus infections associated with blood transfusions. N Engl J Med. 1971;284:1125-31.
69.
YEAGER A, GRUMET F, HAFLEIGH E, ARVIN A, BRADLEY J, and PROBER C. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr. 1981;98:281-7.
70.
DOWLING J, SASLOW A, ARMSTRONG J, and HO M. Cytomegalovirus infection in patients receiving immunosuppressive therapy for rheumatologic disorders. J Infect Dis. 1976;133:399-408.
71.
HO M, SUWANSIRIKUL S, DOWLING J, YOUNGBLOOD L, and ARMSTRONG J. The transplanted kidney as a source of cytomegalovirus infection. N Engl J Med. 1975;293:1109-2.
72.
BETTS R, FREEMAN R, DOUGLAS R, TALLEY T, and RUNDELL B. Transmission of cytomegalovirus infection with renal allograft. Kidney Int. 1975;8:385-92.
73.
NARAQI S, JACKSON G, JONASSON O, and RUBENIS M. Search for latent cytomegalovirus in renal allografts. Infect Immun. 1978;19:699-703.
74.
PREIKSAITIS J, ROSNO S, GRUMET C, and MERIGAN T. Infections due to herpesviruses in cardiac transplant recipients: role of the donor heart and immunosuppressive therapy. J Infect Dis. 1983;147:974-81.
75.
STAGNO S, REYNOLDS D, and TSIANTOS A. Cervical cytomegalovirus excretion in pregnant and nonpregnant women: suppression in early gestation. J Infect Dis. 1975;131:522-7.
76.
WHITLEY R, BRASFIELD D, REYNOLDS D, STAGNO S, TILLER R, and ALFORD C. Protracted pneumonitis in young infants associated with perinatally acquired cytomegaloviral infection. J Pediatr. 1976;89:16-22.
77.
JORDAN M, ROUSSEAU W, NOBLE G, STEWART J, and CHIN T. Association of cervical cytomegaloviruses with venereal disease. N Engl J Med. 1973;288:932-4.
78.
STAGNO S, PASS R, and DWORSKY M. Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N Engl JMed. 1982;306:945-9.
79.
PALOHEIMO J, VON ESSEN R, KLEMOLA E, KÄÄRIÄINEN L, and SILTANEN P. Subclinical cytomegalovirus infections and cytomegalovirus mononucleosis after open heart surgery. Am J Cardiol. 1968;22:624-30.
80.
LANG D, EBERT P, RODGERS B, BOGGESS H, and RIXSE R. Reduction of postperfusion cytomegalovirus-infections following the use of leukocyte-depleted blood. Transfusion. 1977;17:391-5.
81.
TOLKOFF-RUBIN N, RUBIN R, KELLER E, BAKER G, STEWART J, and HIRSCH M. Cytomegalovirus infection in dialysis patients and personnel. Ann Intern Med. 1978;89:625-8.
82.
WINSTON D, HO W, and HOWELL C. Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med. 1980;93:671-5.
83.
HERSMAN J, MEYERS J, THOMAS E, BUCKNER C, and CLIFT R. The effect of granulocyte transfusions on the incidence of cytomegalovirus infection after allogeneic marrow transplantation. Ann Intern Med. 1982;96:149-52.
84.
DIOSI P, MOLDOVAN E, and TOMESCU N. Latent cytomegalovirus infection in blood donors. Br Med J. 1969;4:660-2.
85.
PERHAM T, CAUL E, CONWAY P, and MOTT M. Cytomegalovirus infection in blood donors—a prospective study. Br J Haematol. 1971;20:307-20.
86.
MiRKOVic R, WERCK J, SOUTH M, and BENYESH-MELNICK M. Incidence of cytomegaloviremia in blood bank donors and in infants with congenital cytomegalic inclusion disease. Infect Immun. 1971;3:45-50.
87.
KANE R, ROUSSEAU W, and NOBLE G. Cytomegalovirus infection in a volunteer blood donor population. Infect Immun. 1975;11:719-23.
88.
BAYER W and TEGTMEIER G. The blood donor: detection and magnitude of cytomegalovirus carrier states and the prevalence of cytomegalovirus antibody. Yale J Biol Med. 1976;49:5-12.
89.
LANG D. Cytomegalovirus infections in organ transplantation and posttransfusion: an hypothesis. Arch Gesamte Virus forsch. 1972;37:365-77.
90.
ANDERSEN H and SPENCER E. Cytomegalovirus infection among renal transplant recipients. Acta Med Scand. 1969;186:7-19.
91.
RAND K, POLLARD R, and MERIGAN T. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infections. N Engl J Med. 1978;298:951-3.
92.
GLAZER J, FRIEDMAN H, and GROSSMAN R. Live cytomegalovirus vaccination of renal transplant candidates: a preliminary trial. Ann Intern Med. 1979;91:676-83.
93.
WINSTON D, POLLARD R, and HO W. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med. 1982;97:11-8.
94.
MEYERS J, LESZCZYNSKI J, and ZAIA J. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med. 1983;98:442-6.
95.
PAGANO J. Diseases and mechanisms of persistent DNA virus infection: latency and cellular transformation. J Infect Dis. 1975;132:209-23.
96.
HUANG E and PAGANO J. Nucleic acid hybridization technology and detection of proviral genomes. In: MARAMOROSCH K, KOPROWSKI H, eds. Methods in Virology, Vol. VI. New York: Academic Press; 1977:457-97.
97.
ROCHE J, CHEUNG K, BOLDOGH I, HUANG E, and LANG D. Cytomegalovirus: detection in human colonic and circulating mononuclear cells in association with gastrointestinal disease. Int J Cancer. 1981;27:659-68.
98.
GIRALDO G, BETH E, and HUANG E. Kaposi's sarcoma and its relationship to cytomegalovirus (CMNV): III. CMV DNA and CMV early antigens in Kaposi's sarcoma. Int J Cancer. 1980;26:23-9.
99.
DREW W, CONANT M, and MINER R. Cytomegalovirus and Kaposi's sarcoma in young homosexual men. Lancet. 1982;2:125-7.
100.
CHOU S and MERIGAN T. Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N Engl J Med. 1983;308:921-5.
101.
MARTIN D, KATZENSTEIN D, YU G, and JORDAN M. Cytomegalovirus viremia detected by molecular hybridization and electron microscopy. Ann Intern Med. 1984;100:222-5.
102.
GALL J and PARDUE M. Nucleic acid hybridization in cytological preparations. In: GROSSMAN L, MOLDAVE F, eds. Methods in Enzymology. Vol. 21. New York: Academic Press; 1971:470-80.
103.
JORDAN M, SHANLEY J, and STEVENS J. Immunosuppression reactivates and disseminates latent murine cytomegalovirus. J Gen Virol. 1977;37:419-23.
104.
MAYO D, ARMSTRONG J, and HO M. Reactivation of murine cytomegalovirus by cyclophosphamide. Nature. 1977;267:721-3.
105.
SHANLEY J, JORDAN M, COOK M, and STEVENS J. Pathogenesis of reactivated latent murine cytomegalovirus infection. Am J Pathol. 1979;95:67-80.
106.
JORDAN M. Adverse effects of cytomegalovirus vaccination in mice. J Clin Invest. 1980;65:798-803.
107.
OLDING L, JENSEN F, and OLDSTONE M. Pathogenesis of cytomegalovirus infection: I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. J Exp Med. 1975; 141:56172.
108.
MAYO D, ARMSTRONG J, and HO M. Activation of latent murine cytomegalovirus infection: cocultivation, cell transfer, and the effect of immunosuppression. J Infect Dis. 1978;138:890-6.
109.
JORDAN M, TAKAGI J, and STEVENS J. Activation of latent murine cytomegalovirus in vivo and in vitro: a pathogenetic role for acute infection. J Infect Dis. 1982;145:699-705.
110.
WISE T, MANISCHEWITZ J, QUINNAN G, AULAKH G, and ENNIS F. Latent cytomegalovirus infection in BALB/c mouse spleens detected by expiant culture technique. J Gen Virol. 1979;44:551-6.
111.
JORDAN M and MAR V. Spontaneous activation of latent cytomegalovirus from murine spleen expiants: role of lymphocytes and macrophages in release and replication of virus. J Clin Invest. 1982;70:762-8.
112.
DUTKO F and OLDSTONE M. Cytomegalovirus causes a latent infection in undifferentiated cells and is activated by induction of cell differentiation. J Exp Med. 1981;154:1636-51.
113.
CHEUNG K and LANG D. Detection of latent cytomegalovirus in murine salivary and prostate expiant cultures and cells. Infect Immun. 1977;15:568-74.
114.
DUTKO F and OLDSTONE M. Murine cytomegalovirus infects spermatogenic cells. Proc Natl Acad Sci USA. 1979;76:2988-91.
115.
CHEUNG K and LANG D. Transmission and activation of cytomegalovirus with blood transfusion: a mouse model. J Infect Dis. 1977; 135:8415.
116.
BRAUTIGAM A, DUTKO F, OLDING L, and OLDSTONE M. Pathogenesis of murine cytomegalovirus infection: the macrophage is a permissive cell for cytomegalovirus infection, replication and latency. J Gen Virol. 1979;44:349-59.
117.
NEFF B, WEIBEL R, BUYNAK E, MCLEAN A, and HILLEMAN M. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med. 1979;160:32-7.
118.
GALLOWAY D, COPPLE C, and MCDOUGALL J. Analysis of viral DNA sequences in cells transformed by herpes simplex virus type 2. Proc Natl Acad Sci USA. 1980;77:880-4.
119.
DUFF R and RAPP F. Oncogenic transformation of hamster cells after exposure to herpes simplex virus type 2. Nature [New Biol]. 1971;233:48-50.
120.
MORGAN D, NIEDERMAN J, MILLER G, SMITH H, and DOWALIBY J. Site of Epstein-Barr virus replication in the oropharynx. Lancet. 1979;1:1154-7.
121.
MILLER G, SHOPE T, and COOPE D. Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum, antibody responses, demonstration of viral DNA, and characterization of viruses. J Exp Med. 1977;145:948-67.
122.
ROBINSON J, BROWN N, and ANDIMAN N. Diffuse polyclonal B-cell lymphoma during primary infection with Epstein-Barr virus. N Engl J Med. 1980;302:1293-7.
123.
SCHUBACH W, HACKMAN R, NEIMAN P, MILLER G, and THOMAS E. A monoclonal immunoblastic sarcoma in donor cells bearing Epstein-Barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia. Blood. 1982;60:180-7.
124.
HENDERSON E, ROBINSON J, FRANK A, and MILLER G. Epstein-Barr virus: transformation of lymphocytes separated by size or exposed to bromodeoxyuridine and light. Virology. 1977;82:196-205.
125.
ROBINSON J and SMITH D. Infection of human B lymphocytes with high multiplicities of Epstein-Barr virus: kinetics of EBNA expression, cellular DNA synthesis, and mitosis. Virology. 1981;109:336-43.
126.
BROWN N and MILLER G. Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein-Barr virus. J Immunol. 1982;128:24-9.
127.
STEINITZ M, KLEIN G, KOSKIMIES S, and MAKEL O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature. 1977;269:420-2.
128.
ZURAWSKI V, HABER E, and BLACK P. Production of antibody to tetanus toxoid by continuous human lymphoblastoid cell lines. Science. 1978;199:1439-41.
129.
MILLER G, GROGAN E, HESTON L, ROBINSON J, and SMITH D. EpsteinBarr viral DNA: infectivity for human placental cells. Science. 1981;212:452-5.
130.
BORNKAMM G, DELIUS H, ZIMBER U, HUDEWENTZ J, and EPSTEIN M. Comparison of Epstein-Barr virus strains of different origin by analysis of viral DNA. J Virol 1980;35:603-18.
131.
HELLER M, DAMBAUGH T, and KIEFF E. Epstein-Barr virus DNA: IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol 1981;38:632-48.
132.
FISCHER D, MILLER G, and GRADOVILLE L. Genome of a mononucleosis Epstein-Barr virus contains DNA fragments previously regarded to be unique to Burkitt's lymphoma isolates. Cell 1981;24:54353.
133.
RABSON M, GRADOVILLE L, HESTON L, and MILLER G. Non-immortalizing P3 J-HR-I Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye. J Virol. 1982;44:834-44.
134.
SUMMERS W, GROGAN E, SHEDD D, ROBERT M, LIU C, and MILLER G. Stable expression in mouse cells of nuclear neoantigen after transfer of a 3.4-megadalton cloned fragment of Epstein-Barr virus DNA. Proc Natl Acad Sci USA. 1982;79:5688-92.
135.
WIGLER M, SILVERSTEIN S, LEE L, PELLICER A, CHENG Y, and AXEL R. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell. 1977;11:223-32.
136.
BRANDSMA J and MILLER G. Nucleic acid spot hybridization: rapid quantitative screening of lymphoid cell lines for Epstein-Barr viral DNA. Proc Natl Acad Sci USA. 1980;77:6851-5.
137.
ENDERS J, WELLER T, and ROBBINS F. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science. 1949;109:85-7.
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 100 • Number 6 • 1 June 1984
Pages: 866 - 880
History
Published in issue: 1 June 1984
Published online: 1 December 2008
Keywords
- Cancers and neoplasms
- Carcinoma
- Cell biology
- Cells
- DNA
- DNA viruses
- Epithelial cells
- Ganglia
- Genetics
- Genitourinary infections
- Hematology and oncology
- Herpesviruses
- Human cytomegalovirus
- Infectious diseases
- Lymphocytes
- Nervous system
- Neurology
- Neurons
- Research and reporting methods
- Urology
- Viral diseases
- White blood cells
Copyright
© 1984 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Latent Herpesviruses of Humans. Ann Intern Med.1984;100:866-880. doi:10.7326/0003-4819-100-6-866
Latent Herpesviruses of Humans. Ann Intern Med.1984;100:866-880. doi:10.7326/0003-4819-100-6-866
View More
Get Access
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.